CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
0.7406
2.54%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0124
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-4.47)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.25)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.7284
Open 0.737
1-Year Change 29.98%
Day's Range 0.7339 - 0.75
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 29, 2025 0.7284 0.0215 3.04% 0.7069 0.7432 0.7069
Jan 28, 2025 0.7094 -0.0175 -2.41% 0.7269 0.7269 0.7008
Jan 27, 2025 0.7270 -0.0498 -6.41% 0.7768 0.7824 0.7099
Jan 24, 2025 0.7712 -0.0128 -1.63% 0.7840 0.8148 0.7669
Jan 23, 2025 0.7715 0.0245 3.28% 0.7470 0.7834 0.7269
Jan 22, 2025 0.7534 0.0064 0.86% 0.7470 0.7604 0.7389
Jan 21, 2025 0.7423 0.0134 1.84% 0.7289 0.7603 0.7125
Jan 17, 2025 0.7029 -0.0139 -1.94% 0.7168 0.7203 0.6979
Jan 16, 2025 0.7096 -0.0233 -3.18% 0.7329 0.7329 0.6969
Jan 15, 2025 0.7177 -0.0192 -2.61% 0.7369 0.7381 0.6872
Jan 14, 2025 0.7269 -0.0315 -4.15% 0.7584 0.7584 0.7269
Jan 13, 2025 0.7469 -0.0500 -6.27% 0.7969 0.7970 0.7296
Jan 10, 2025 0.7807 -0.0469 -5.67% 0.8276 0.8276 0.7769
Jan 8, 2025 0.8269 -0.0400 -4.61% 0.8669 0.8689 0.8128
Jan 7, 2025 0.8709 -0.0360 -3.97% 0.9069 0.9189 0.8684
Jan 6, 2025 0.8884 -0.0385 -4.15% 0.9269 0.9269 0.8691
Jan 3, 2025 0.8869 -0.0967 -9.83% 0.9836 0.9869 0.8788
Jan 2, 2025 0.8990 0.0420 4.90% 0.8570 0.9656 0.8369
Dec 31, 2024 0.8022 -0.0048 -0.59% 0.8070 0.8323 0.7869
Dec 30, 2024 0.8019 -0.0550 -6.42% 0.8569 0.8570 0.7833

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

People also watch

XRP/USD

3.13 Price
+1.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01563

ETH/USD

3,272.95 Price
+4.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

21,466.20 Price
+0.210% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,793.84 Price
+1.130% 1D Chg, %
Long position overnight fee -0.0016%
Short position overnight fee -0.0066%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading